FC-L
H
Endogenous
60
Rabbit IgG
#P43628
3804
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Flow Cytometry (Live) | 1:100 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala173 of human KIR2DL3 protein.
Background
Killer cell immunoglobulin-like receptors (KIRs) are type 1 transmembrane glycoproteins expressed by natural killer (NK) cells and subsets of CD4, CD8, and γδ T cells (1-5). Analogous to the diversity of their human leukocyte antigen class I (HLA class I) ligands, the KIR genes are polymorphic and the content of the KIR gene cluster varies among haplotypes, although several "framework" genes are found in all haplotypes (6,7). The KIR proteins are characterized by the number of extracellular immunoglobulin-superfamily domains (2D or 3D) and by whether they have a long (L) or short (S) cytoplasmic domain (8-10). KIR proteins with the long cytoplasmic domain transduce inhibitory signals upon ligand binding via an immune tyrosine-based inhibitory motif (ITIM) (10), while KIR proteins with the short cytoplasmic domain lack an ITIM and instead transduce activating signals (11,12). KIR proteins play an important role in the regulation of the immune response. Combinations of KIR and HLA class I variants influence susceptibility to autoimmunity and infectious disease, as well as outcomes of haematopoietic stem cell transplantation (12-14).
KIR2DL3, also referred to as CD158b, interacts with HLA-C alleles (HLA-Cw1, HLA-Cw3, and HLA-Cw7). Upon receptor ligand interaction, KIR2DL3 inhibits the activity of NK cells thus preventing target cell lysis (15-17).
- Young, N.T. et al. (2001) J Immunol 166, 3933-41.
- Battistini, L. et al. (1997) J Immunol 159, 3723-30.
- Björkström, N.K. et al. (2012) Blood 120, 3455-65.
- Remtoula, N. et al. (2008) J Immunol 180, 2767-71.
- Béziat, V. et al. (2017) Immunology 150, 248-264.
- Uhrberg, M. et al. (1997) Immunity 7, 753-63.
- Shilling, H.G. et al. (2002) J Immunol 168, 2307-15.
- Fan, Q.R. et al. (2001) Nat Immunol 2, 452-60.
- Boyington, J.C. et al. (2000) Nature 405, 537-43.
- Vivian, J.P. et al. (2011) Nature 479, 401-5.
- Stewart, C.A. et al. (2005) Proc Natl Acad Sci USA 102, 13224-9.
- Ivarsson, M.A. et al. (2014) Front Immunol 5, 184.
- Kulkarni, S. et al. (2008) Semin Immunol 20, 343-52.
- Martin, M.P. and Carrington, M. (2013) Immunol Rev 254, 245-64.
- Colonna, M. et al. (1993) Proc Natl Acad Sci U S A 90, 12000-4.
- Winter, C.C. et al. (1998) J Immunol 161, 571-7.
- Moesta, A.K. et al. (2008) J Immunol 180, 3969-79.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Applications Key
FC-L: Flow Cytometry (Live)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.